The introduction of intravitreal vascular endothelial growth factor (VEGF) inhibitor therapy has revolutionized treatment for neovascular age-related macular degeneration (nAMD), retinal vein occlusion (RVO), and diabetic macular edema (DME) and halved the number of people aged 50 years or older newly diagnosed with blindness.1 The number of patients receiving VEGF inhibitors is expected to escalate as life expectancy increases,2,3 influencing strategic planning for future ophthalmological services. Here, VEGFA is linked to wet macular degeneration.